3-(1'-benzoyl-4-oxospiro[3H-chromene-2,4'-piperidine]-7-yl)-N-(oxan-2-yloxy)prop-2-enamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(1'-benzoyl-4-oxospiro[3H-chromene-2,4'-piperidine]-7-yl)-N-(oxan-2-yloxy)prop-2-enamide
• 化学式: C₂₈H₃₀N₂O₆
• 分子量: 490.5
• InChiKey: LHTKKOMBNOBKOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  94.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Spirocyclic derivatives as histone deacetylase inhibitors
  申请人：DAC S.r.l.

  公开号：EP2110377A1

  公开（公告）日：2009-10-21

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; n is zero or an integer from 1 to 4; R1 is hydrogen; C1-C6 alkyl, optionally substituted by aryl or by heteroaryl; (CO)R3; (SO2)R4; aryl; or heteroaryl; R2 is C1-C6 alkyl, optionally substituted by aryl or by heteroaryl; aryl; heteroaryl; or (CO)R5; X is CH2, oxygen or NR6; Y is a bond, CHR7 or NR8; Z is oxygen, CR9R10 or C=R11; and R3, R4, R5, R6, R3 R8, R9, R10 and R11 are as further defined in the specification; and pharmaceutical acceptable salts thereof.

  这项发明涉及新的组蛋白去乙酰化酶抑制剂，其一般公式为（I），其中：虚线是可选的附加键；n为零或1至4之间的整数；R1为氢；C1-C6烷基，可选地被芳基或杂环烷基取代；（CO）R3；（SO2）R4；芳基；或杂环烷基；R2为C1-C6烷基，可选地被芳基或杂环烷基取代；芳基；杂环烷基；或（CO）R5；X为CH2，氧或NR6；Y为键，CHR7或NR8；Z为氧，CR9R10或C=R11；而R3、R4、R5、R6、R3、R8、R9、R10和R11如规范中进一步定义；以及其药用可接受的盐。
• SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
  申请人：Varasi Mario

  公开号：US20140080823A1

  公开（公告）日：2014-03-20

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; n is zero or an integer from 1 to 4; R 1 is hydrogen; C 1 -C 6 alkyl, optionally substituted by cycloalkyl, aryl or by heteroaryl; (CO)R 3 ; (SO 2 )R 4 ; cycloalkyl; aryl; or heteroaryl; R 2 is C 1 -C 6 alkyl, optionally substituted by aryl or by heteroaryl; aryl; heteroaryl; or (CO)R 5 ; X is CH 2 , oxygen or NR 6 ; Y is a bond, CHR 7 or NR 8 ; Z is oxygen, CR 9 R 10 or C═R 11 ; and R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are as further defined in the specification; and pharmaceutical acceptable salts thereof.

  本发明涉及新的组蛋白去乙酰化酶抑制剂，其通式为(I)，其中：虚线是可选的额外键；n为零或1至4的整数；R1为氢；C1-C6烷基，可选地被环烷基、芳基或杂芳基取代；(CO)R3；(SO2)R4；环烷基；芳基；或杂芳基；R2为C1-C6烷基，可选地被芳基或杂芳基取代；芳基；杂芳基；或(CO)R5；X为CH2、氧或NR6；Y为键、CHR7或NR8；Z为氧、CR9R10或C═R11；而R3、R4、R5、R6、R7、R8、R9、R10和R11如规范中所进一步定义的；以及其药学上可接受的盐。
• US8592444B2
  申请人：——

  公开号：US8592444B2

  公开（公告）日：2013-11-26
• US9115148B2
  申请人：——

  公开号：US9115148B2

  公开（公告）日：2015-08-25